Cited by 2,118Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Open access

Yun, Cai-Hong, Mengwasser, Kristen E., Toms, Angela V., Woo, Michele S., Greulich, Heidi, Wong, Kwok-Kin, Meyerson, Matthew, Eck, Michael J.·2008·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0709662105PMC PMC2538882

Open this paper in CoChat — free account

Abstract

Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M. Threonine 790 is the “gatekeeper” residue, an important determinant of inhibitor specificity in the ATP binding pocket. The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors. Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib. Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude. The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance. Crystallographic analysis of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation. We conclude that the T790M mutation is a “generic” resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0709662105

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse‐Kunstleve, R. W., Jiang, J., Kuszewski, J. J., Nilges, M., Pannu, N., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,723
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,837
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Show all 42 references

Research works printed but not linked: 1

10.1128/mcb.6.12.4155-4160.1986 · DOI

Sorted by citations

Items 701–800 of 1,002

Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
Tao, G., & Chityala, P. K. (2021) · Toxicology Research · doi:10.1093/toxres/tfab026 · Cited by 39
A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
Heppner, D. E., & Eck, M. J. (2021) · Protein Science · doi:10.1002/pro.4125 · Cited by 39
“Resistance invariably develops to the first- and second-generation agents described above, most commonly due to a second mutation in the EGFR kinase domain, T790M.(45,46) The T790M mutation lies at the back of the ATP-site, altering the shape of the inhibitor binding site.”
BackgroundInfluentialSelf-citation
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
“, 2002) or increased affinity for a physiological compound competing for the same drug binding site within the target (Yun et al., 2008).”
Background
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Cadranel, J. L., Zalcman, G., & Sequist, L. V. D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00179409 · Cited by 39
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors
Qin, X., Lv, Y., Liu, P., Li, Z., Hu, L., Zeng, C., & Yang, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.009 · Cited by 38
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future
Proto, C., Imbimbo, M., Gallucci, R., Brissa, A., Signorelli, D., Vitali, M., Macerelli, M., Corrao, G., Ganzinelli, M., Greco, F. G., et al. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.16 · Cited by 37
“The substitution of methionine with threonine at position 790 in the exon 20 blocks the binding of first generation EGFR-TKIs to the ATP pocket and increases its affinity to ATP rather than to EGFR-TKIs (126,127).”
Background
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3263-z · Cited by 38
“More importantly, however, it restores the affinity for ATP, similar to that of wild-type EGFR [43].”
Background
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance
Xu, C., Wu, P., Gao, J., Zhang, L., Ma, T., Ma, B., Yang, S., Shao, G., Yu, Y., Huang, X., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7130 · Cited by 38
“However, patients with NSCLC who initially respond to EGFR-TKIs often acquire resistance due to the secondary mutations of EGFR, including T790M (5).”
Background
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
“Given that the T790M mutation restores ATP affinity to a level comparable to that of WT EGFR (Yun et al., 2008), concentrations of second-generation TKIs necessary to inhibit T790M-mutated tumors in patients may result in side effects that ultimately limit their use.”
Background
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations
He, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 38
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
Zhang, S., Zheng, X., Huang, H., Wu, K., Wang, B., Chen, X., & Ma, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3332 · Cited by 39
“In NSCLC cells with initial EGFR-L858R mutation, the presence of secondary T790M mutation was found to affect the binding of gefitinib to mutated EGFR, with increased affinity of L858-T790M-EGFR to ATP when compared to L858 alone [30].”
Regulation of the Ligand-dependent Activation of the Epidermal Growth Factor Receptor by Calmodulin
Li, H., Panina, S., Kaur, A., Ruano, M. J., Sánchez‐González, P., la Cour, J. M., Stephan, A., Olesen, U. H., Berchtold, M. W., & Villalobo, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.317529 · Cited by 37
“4mMdepending of the cell type (50), and the affinity constant ofATP for the EGFR is lower than 10 M (51, 52).”
Background
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
Savonarola, A., Palmirotta, R., Guadagni, F., & Silvestris, F. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.28 · Cited by 36
Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants
Xu, T., Zhang, L., Xu, S., Yang, C., Luo, J., Ding, F., Lu, X., Liu, Y., Tu, Z., Li, S., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302313 · Cited by 37
Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase
Ruan, Z., & Kannan, N. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00444 · Cited by 37
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Jin, Y., Shao, Y. W., Shi, X., Lou, G., Zhang, Y., Wu, X., Tong, X., & Yu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.11237 · Cited by 37
“Currently, the known mechanisms of acquired resistance are as follows [13-17]: 1) the secondary gatekeeper EGFR T790M mutation which increases ATP affinity and subsequently prevents drug binding to the kinase domain; 2) activation of members of downstream signaling pathways such as RAS-RAF-ERK MAPK pathway and PI3K/AK…”
Background
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37
Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents
Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
Zou, B., Lee, V. H.-F., & Yan, H. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2093-6 · Cited by 37
“Another is that introduction of the T790 M mutation increases the affinity for adenosine triphosphate (ATP) which reduces binding of competing TKIs such as gefitinib and erlotinib [19, 20, 32].”
Background
Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer
Cha, M. Y., Lee, K., Kim, J. W., Lee, C. G., Song, J. Y., Kim, Y. H., Lee, G. S., Park, S. B., & Kim, M. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901146p · Cited by 37
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
“This mutation is thought to block the binding of inhibitors to the ATP-binding site, thus leading to the constitutive activation of EGFR [112].”
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
Nurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
“[35] Yun C-H, Mengwasser KE, Toms AV, et al.”
Background
p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles
Kaur, J., & Tikoo, K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.01.029 · Cited by 37
“But recent studies have showed that T790M mutants retain low nanomolar affinity for gefitinib and the drug resistance in these mutants has been proposed to be due to the restoration of ATP affinity to the level of wild type levels [5].”
Background
Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications
Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Lee, J. Y., Sun, J.-M., Lim, S. H., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H.-N., Ku, B. M., Koh, J., Bae, Y.-H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1653 · Cited by 36
“Approximately half of patients have a secondary EGFR mutation in exon 20 (T790M), which is proposed to cause resistance by interfering with binding of TKIs or by increasing the affinity for ATP (11, 12).”
Background
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR
Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Clausen, S., Dotson, J., Eigenbrot, C. W., Elliott, R. L., Hanan, E. J., Heald, R. A., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00428 · Cited by 36
Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada
Stockley, T. L., Souza, C. A., Cheema, P. K., Melosky, B. L., Kamel‐Reid, S., Tsao, M., Spatz, A., & Karsan, A. (2018) · Current Oncology · doi:10.3747/co.25.4044 · Cited by 37
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
“Threonine 790 is the gatekeeper for EGFR because it is located at the entrance to the hydrophobic ATP-binding pocket; this mutation promotes cancer cell proliferation via increasing the catalytic activity of EGFR [17].”
Background
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs
Wan, S., & Coveney, P. V. (2011) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0609 · Cited by 36
EGFR inhibition in non-small cell lung cancer: current evidence and future directions
Chi, A., Remick, S. C., & Tse, W. W. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-2 · Cited by 35
“T790M may increase the GTP affinity in the tyrosine kinase domain of the EGFR, or hindrance to TKI binding to the tyrosine kinase domain [75,76].”
Conformational regulation of the EGFR kinase core by the juxtamembrane and C‐terminal tail: A molecular dynamics study
Mustafa, M., Mirza, A., & Kannan, N. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22862 · Cited by 36
Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells
Mathew, M. P., Tan, E., Saeui, C. T., Bovonratwet, P., Sklar, S., Bhattacharya, R., & Yarema, K. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11582 · Cited by 34
“In particular, 1,3,4-O-Bu3ManNAc sensitized drug-resistant pancreatic cancer cells to the tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib [1] that are currently used as cancer therapeutics but are only modestly effective because of rapid onset drug resistance in patients [35].”
BackgroundInfluential
Recent advances in multitarget-directed ligands via in silico drug discovery
Krishnaiah, M., Yada, B., Kumari, S., McHale, C. C., Pal, D., & Durden, D. L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103904 · Cited by 38
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications
Baldi, S., Long, N., Ma, S., Liu, L., Al-Danakh, A., Qin, Y., Deng, X., Xie, J., & Tang, H. (2025) · Research · doi:10.34133/research.0747 · Cited by 44
“For example, T790M is a known resistance mutation in EGFR that notably reduces the potency of first-generation inhibitors [ 25 ].”
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
Wang, D. D., Ma, L., Wong, M. P., Lee, V. H.-F., & Yan, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128360 · Cited by 35
“As mutations L858R_T790M and delL747_P753insS largely corresponded to poor clinical outcomes and active TKI resistance [16, 22, 23, 53], their decreased binding with ErbB-3 may encourage the binding between cMet and ErbB-3, which strengthens the ErbB-3 downstream signaling.”
BackgroundResultInfluential
New molecular targeted therapies for advanced non-small-cell lung cancer.
Méndez, M., Custodio, A., & Provencio, M. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.03 · Cited by 34
“Instead, L858R-T790MEGFR had greater affinity to ATP than L858R alone, which is predicted to decrease binding of gefitinib and erlotinib, because these drugs are ATP-competitive kinase inhibitors (7).”
Background
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
Gately, K. A., O’Flaherty, J. D., Cappuzzo, F., Pirker, R., Kerr, K. M., & O'Byrne, K. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200275 · Cited by 35
“The T790M mutation may result in increased affinity of EGFR for ATP compared with erlotinib or gefitinib and that this is the primary mechanism by which the mutation confers drug resistance.(51) Thus, it should be possible to overcome the resistance by developing TKIs that have a higher affinity for the T790M kinase.”
Background
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
Asami, K., Okuma, T., Hirashima, T., Kawahara, M., Atagi, S., Kawaguchi, T., Okishio, K., Omachi, N., & Takeuchi, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.022 · Cited by 35
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
Landi, L. M., Tiseo, M., Chiari, R., Ricciardi, S., Rossi, E., Galetta, D., Novello, S., Milella, M., D’Incecco, A., Minuti, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.002 · Cited by 35
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Xue, Y., Hou, S., Ji, H., & Han, X. (2016) · Protein & Cell · doi:10.1007/s13238-016-0330-1 · Cited by 35
“It was discovered that ATP-binding cassette subfamily B member 1 (ABCB1) overexpression, which was associated with cancer stem cell (CSC) properties and EMT, was involved in the acquired resistance to MET inhibitors.”
BackgroundInfluential
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
Mao, X., Chen, Z., Zhao, Y., Yu, Y., Guan, S., Woodfield, S. E., Vasudevan, S. A., Tao, L., Pang, J. C., Lu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13657 · Cited by 35
“Compared to wild type EGFR, proteins coded for with the gene with the T790M mutation have a 5-fold increased efficacy of kinase activation [51]; this increased activity is responsible for the poor outcome of lung cancer patients [52].”
Background
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
Skoulidis, F., & Papadimitrakopoulou, V. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2815 · Cited by 35
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Liang, Z., Cheng, Y., Chen, Y., Hu, Y., Liu, W.-P., Lü, Y., Wang, J., Wang, Y., Wu, G., Ying, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.008 · Cited by 36
Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
Saldaña-Rivera, L., Bello, M., & Méndez-Luna, D. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1558112 · Cited by 34
“…stabilized structures for wild-type EGFRD and EGFRD-L858R-T790M than for EGFRD-L858R and EGFRD-T790M and indicate that the insertion of the T790M mutation into L858R mutants resembles the wild-type EGFR structure based on the restoration of ATP affinity to near wild-type levels (Yun et al., 2008).”
BackgroundResultInfluential
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
Chang, L.-C., Lim, C., Chang, L., Chen, K., Shih, J., & Yu, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.025 · Cited by 35
Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations
Xiao, Z., Zhou, Z., Chu, C., Zhang, Q., Zhou, L., Yang, Z., Li, X., Yu, L., Zheng, P., Xu, S., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112511 · Cited by 36
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
“These common canonical mutants lead to structural changes that change ATP kinetics, enhance EGFR activation (promoting an “on” instead of “off” switch), and generate a favorable therapeutic window to almost all EGFR TKIs that have completed clinical development, including: 1 generation reversible inhibitors (gefitinib…”
EGFR AP : a predictive machine learning model for assessing small molecule activity against the epidermal growth factor receptor
Gupta, A., Thind, A. S., & Purohit, R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00361j · Cited by 37
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
Chan, B. K., Hanan, E. J., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, E. W., Chen, Y., Clausen, S., Vega, T. D., Dotson, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00995 · Cited by 38
MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
Xu, B., Zhao, Y., Wang, X., et al. (2016) · Leukemia · doi:10.1038/leu.2016.297 · Cited by 34
Synthesis, Characterization, and Biological Activity of a Novel Series of Benzo[4,5]imidazo[2,1-b]thiazole Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors
Deng, X., Tan, X., An, T., Ma, Q., Jin, Z. H., Wang, C., Meng, Q., & Hu, C. (2019) · Molecules · doi:10.3390/molecules24040682 · Cited by 35
Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing
Ng, C. C. Y., Nasir, N. D. M., Loke, B. N., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00787-w · Cited by 34
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
Zhao, H., Xi, X.-X., Xin, M., & Zhang, S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106057 · Cited by 43
Treatment of nonsmall cell lung cancer
Carter, C. A., & Giaccone, G. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834ec6a7 · Cited by 34
“Second-generation TKIs targeting EGFR have a higher affinity for the ATP-binding domain and form an irreversible covalent bond to the ATPbinding site.”
BackgroundInfluential
Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor
Wan, S., & Coveney, P. V. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.21866 · Cited by 34
C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant
Xu, T., Peng, T., Ren, X., Zhang, L., Yu, L., Luo, J., Zhang, Z., Tu, Z., Tong, L., Huang, Z., et al. (2015) · MedChemComm · doi:10.1039/c5md00208g · Cited by 34
FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Xiao, Y., Yin, C., Wang, Y., Lv, H., Wang, W., Huang, Y., Pérez‐Losada, J., Snijders, A. M., Mao, J., & Zhang, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12200 · Cited by 34
“Among those resistance mechanisms, the secondary EGFR mutation, T790M in exon 20 of the EGFR gene, plays the most significant role and arises in ~ 60% of the cases (Sun et al., 2013; Sutto and Gervasio, 2013; Yun et al., 2008).”
Background
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33
Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity
Aboelez, M. O., El‐Remaily, M. A. E. A. A. A., Kamel, M. S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108728 · Cited by 33
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Whitsett, T. G., Richer, A. L., Friel, J. M., Carson, V. M., & Inge, L. J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52845 · Cited by 35
Going for broke: targeting the human cancer pseudokinome
Bailey, F. P., Byrne, D. P., McSkimming, D. I., Kannan, N., & Eyers, P. A. (2015) · Biochemical Journal · doi:10.1042/bj20141060 · Cited by 33
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode
Wang, A., Li, X., Wu, H., Zou, F., Yan, X.-E., Cheng, C., Hu, C., Yu, K., Wang, W., Zhao, P., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01907 · Cited by 35
Self-citation
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations
Wan, S., Yan, R., Jiang, Y., Li, Z., Zhang, J., & Wu, X. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1552197 · Cited by 35
“The most common secondary somatic T790M mutation at the gatekeeper position within the ATP site of receptor confers resistance by enhancing the affinity for ATP, thereby reducing the potency of ATP-competitive inhibitors (Yun et al., 2008).”
Background
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni, D. O., Miller, B., Kuhlmann, A., Ho, P., Robles-Oteíza, C., Gaefele, M., Levy, S., de Miguel, F. J., Perry, C. J., Guan, T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0643-8 · Cited by 32
Allosteric p97 Inhibitors Can Overcome Resistance to ATP‐Competitive p97 Inhibitors for Potential Anticancer Therapy
Wang., F., Li, S., Gan, T., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900722 · Cited by 33
Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach
Agarwal, S. M., Nandekar, P. P., & Saini, R. P. (2022) · RSC Advances · doi:10.1039/d2ra00373b · Cited by 35
Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy
Ali, A. M., Tawfik, S. S., Mostafa, A. S., & Massoud, M. A. M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14130 · Cited by 33
Gold nanostructure-mediated delivery of anticancer agents: Biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers
Entezari, M., Abad, G. G. Y., Sedghi, B., Ettehadi, R., Asadi, S., Beiranvand, R., Haratian, N., Karimian, S. S., Jebali, A., Khorrami, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115673 · Cited by 35
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Wang, C., Zhang, Y., Chen, W., Wang, Y., & Xing, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188927 · Cited by 34
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer
Anoosha, P., Huang, L., Sakthivel, R., Karunagaran, D., & Gromiha, M. M. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.07.005 · Cited by 33
An In Vivo C. elegans Model System for Screening EGFR-Inhibiting Anti-Cancer Drugs
Bae, Y., Sung, J. Y., Kim, Y.-N., Kim, S., Hong, K. M., Kim, H. T., Choi, M. S., Kwon, J. Y., & Shim, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042441 · Cited by 32
“The T790M mutation may result in an alteration of EGFR topology that precludes the binding of reversible EGFR-TKIs through steric hindrance, or T790M may increase the affinity of the kinase domain for ATP [21,33–35].”
Background
siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells
Yuan, L., Liu, L., Wang, Y., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.036 · Cited by 33
“Inhibitors of the MET protein have been tested in clinical trials, but no compelling evidence of a clinical benefit was obtained in NSCLC patients whose initial treatment with TKIs failed [29].”
BackgroundInfluential
Synthesis, Reactivity, and Biological Activity of Gold(I) Complexes Modified with Thiourea-Functionalized Tyrosine Kinase Inhibitors
Yang, M., Pickard, A. J., Qiao, X., Gueble, M. J., Day, C. S., Kucera, G. L., & Bierbach, U. (2015) · Inorganic Chemistry · doi:10.1021/ic502998a · Cited by 33
The Role of Pathologists in the Era of Personalized Medicine
Walk, E. E. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.605 · Cited by 33
Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer
Brown, B. P., Zhang, Y., Kim, S., Finneran, P., Yan, Y., Du, Z., Kim, J., Hartzler, A. L., Lenoue-Newton, M. L., Smith, A. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206588119 · Cited by 31
“, L858R by several orders of magnitude (48); 393 instead, the difference is ~6x.”
Influential
The new concepts on overcoming drug resistance in lung cancer
Dong, X., Xu, C., Lei, P., & Zhang, W. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s60672 · Cited by 32
“28 T790M mutation accounts for 50% of all the EGFR-specific resistance; it facilitates phosphorylation of EGFR despite the presence of a TKI through increasing the affinity of mutant EGFR for ATP.”
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation
Zhao, B.-X., Wang, J., Song, B., WEI, H., Lv, W., TIAN, L.-M., Li, M., & Lv, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3058 · Cited by 32
“Some studies have suggested that the T790M mutation most likely causes acquired drug resistance by enhancing the ATP affinity of EGFR L858R, and thus reducing the efficacy of the ATP‑competitive TKIs (17).”
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Franco, R., Rocco, G., Marino, F. Z., Pirozzi, G., Normanno, N., Morabito, A., Sperlongano, P., Stiuso, P., Luce, A., Botti, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.18 · Cited by 32
Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Jang, J.-Y., Kim, Y.-G., Nam, S. J., Keam, B., Kim, T. M., Jeon, Y. K., & Kim, C. W. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0089 · Cited by 31
Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties
Xu, S., Xu, T., Zhang, L., Zhang, Z., Luo, J., Liu, Y., Lu, X., Tu, Z., Ren, X., & Ding, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012388 · Cited by 33
Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design
Albanaz, A. T. S., Rodrigues, C. H. M., Pires, D. E. V., & Ascher, D. B. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1322579 · Cited by 33
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors
Orlandi, P., Desidero, T. D., Salvia, G., Muscatello, B., Francia, G., & Bocci, G. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.011 · Cited by 32
Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
Mao, J., Ma, L., Shen, Y., Zhu, K., Zhang, R., Xi, W., Ruan, Z., Luo, C. Y., Chen, Z., Xi, X., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0998-7 · Cited by 32
Evolution of Small Molecule Kinase Drugs
Lightfoot, H. L., Goldberg, F. W., & Sedelmeier, J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00445 · Cited by 34
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
Kim, D., Lee, K. H., Han, J., Lee, J.-S., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J.-S., Min, Y. J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.007 · Cited by 33
A photosensitizer-inhibitor conjugate for photodynamic therapy with simultaneous inhibition of treatment escape pathways
Xiao, M., Fan, J., Li, M., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120262 · Cited by 32
Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib’s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach
Patel, H., Ahmad, I., Jadhav, H., Pawara, R. H., Lokwani, D. K., & Surana, S. J. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666201204125524 · Cited by 32
Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR
Silveira, C., Sousa, A. C., Janeiro, A., Malveiro, S., Teixeira, E., Brysch, E. C. D. S. V., Pantarotto, M., Felizardo, M., Madureira, R., Nogueira, F., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1010 · Cited by 32
“This mutation leads to an enhanced affinity for ATP, thus reducing the ability of ATP-competitive reversible EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, to bind to the tyrosine kinase domain of EGFR (14).”
Background
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Papini, F., Sundaresan, J., Leonetti, A., Tiseo, M., Rolfo, C. D., Peters, G. J., & Giovannetti, E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103454 · Cited by 35
Treatment Represents a Key Driver of Metastatic Cancer Evolution
Christensen, D. S., Ahrenfeldt, J., Sokač, M., Kisistók, J., Thomsen, M. K., Maretty, L., McGranahan, N., & Birkbak, N. J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0562 · Cited by 34
“…in metastatic Gastrointestinal Stromal tumors, previously associated with acquired resistance to imatinib(26), and the EGFR T790M mutation was found significantly enriched in metastatic non-small cell lung cancer, a well documented resistance mutation to anti-EGFR therapies(27) (Figure 4B).”
Background
Side effects of tyrosine kinase inhibitors therapy in patients with non‑small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta‑analysis
Obradović, J., Todosijević, J., & Jurišić, V. (2022) · Oncology Letters · doi:10.3892/ol.2022.13649 · Cited by 32
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib
Mathew, M. P., Tan, E., Saeui, C. T., Bovonratwet, P., Liu, L., Bhattacharya, R., & Yarema, K. J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.060 · Cited by 31
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre, N., Zoete, V., Michielin, O. A., Stauffer, E., Zimmermann, D. R., Betticher, D. C., & Peters, S. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.013 · Cited by 32
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis
Jeong, C. (2015) · Journal of Cancer Prevention · doi:10.15430/jcp.2015.20.1.57 · Cited by 33
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors
Xiao, Q., Qu, R., Gao, D., Qi, Y., Tong, L., Zhang, W., Ding, J., Xie, H., & Li, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.032 · Cited by 32
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines
Yu, H., Li, Y., Yang, G., Song, Z., Wang, C., Huang, S., Jin, Y., Han, X., Zhen, Y., Liu, K., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.045 · Cited by 33
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review
Galli, G., Corrao, G., Imbimbo, M., Proto, C., Signorelli, D., Ganzinelli, M., Zilembo, N., Vitali, M., de Braud, F., Garassino, M. C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.002 · Cited by 29

Authors: Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J.
Affiliations: Dana-Farber Cancer Institute (US)
Broad Institute (US)
Brigham and Women's Hospital (US)
Corresponding author: Eck, Michael J.
ORCID: Yun, Cai-Hong
Greulich, Heidi
Wong, Kwok-Kin
Meyerson, Matthew
Eck, Michael J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2008-02-12
Volume: 105
Issue: 6
Pages: 2070-2075
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0709662105
PMC: PMC2538882
OpenAlex: W2159013299
Cited by: 2,118
References: 42
Citations by year: 2026: 101 · 2025: 125 · 2024: 94 · 2023: 141 · 2022: 132 · 2021: 138 · 2020: 107 · 2019: 111 · 2018: 144 · 2017: 142 · 2016: 139 · 2015: 143 · 2014: 112 · 2013: 121 · 2012: 115
FWCI: 79.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders: Leukemia and Lymphoma Society
National Institutes of Health
Novartis Institutes for BioMedical Research
National Cancer Institute (R01CA116020, CA 116020, R01CA080942, CA080942)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: T790M mutation, EGFR, drug resistance, tyrosine kinase inhibitors, gefitinib, erlotinib, ATP affinity, gatekeeper residue, L858R mutation, irreversible inhibitors, covalent binding, kinase activation, lung cancer, ATP-competitive inhibitors
MeSH terms: Gefitinib, Adenosine Triphosphate, Animals, Drug Resistance, Enzyme Inhibitors, Insecta, Kinetics, Mutation, Protein Conformation, Quinazolines, Crystallography, X-Ray, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks